Acil serviste pulmoner emboli tanısı alan hastalarda serum trombosit kaynaklı büyüme faktörü-beta(PDGF-β) düzeylerinin araştırılması
Yükleniyor...
Dosyalar
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Trakya Üniversitesi Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Pulmoner emboli, akut miyokard infarktüsü ve inmeden sonra en sık görülen vasküler hastalıktır. Hastalara tanı koyulmadan mortalite görüldüğü için tam olarak prevelansı net bilinmemektedir. Bu akut patoloji nedeniyle sağ kalp yetmezliğinden ani kardiyak arreste kadar sonuçlar ortaya çıkabileceğinden hızlı tanı konulmalı ve tedavi başlanmalıdır. D-dimer gibi laboratuar testleri bulunsa da bunların duyarlılığı az olduğundan yeni biyobelirteçlere ihtiyaç duyulmaktadır. Çalışmamızda bu belirteçlerden biri olabileceği düşünülen PDGFB’nin PE olgularında tanısal değerliliği araştırılmak istendi. Çalışmamız 3.basamak bir üniversite acil servisinde prospektif ve tek merkezli olarak yapıldı. Çalışmamıza, çalışmaya dahil edilme kriterlerini karşılayan 44 hasta ve 34 kontrol grubu şeklinde 78 kişi dahil edildi. Çalışmamızda anlamlılık düzeyi p<0,05 olarak kabul edildi. Çalışmamızda pulmoner emboli olgularının yaş ortalaması 68,9±13 (40-96) yıl olarak tespit edildi. Hasta grubunda olguların %56,8’i (n=25) kadın ve %43,2’si (n=19) erkekti. PDGF-B düzeyinin hasta olgularda ortalama 994,5±541 ve kontrol grubunda 748±411,5 olduğu ve hasta grubundan istatistiksel anlamlı yüksek olduğu görüldü (p<0,05). PDGF-B ile olguların yaşı, cinsiyetleri, kronik hastalıkları varlığı, vital bulguları, hesaplanan Geneva, Wells ve PESİ skorları, D-dimer düzeyleri ve laboratuar sonuçları, mortalite durumları ve ekokardiyografi değerlendirmeleri arasında istatistiksel ilişki gözlemlenmedi. Çalışmamızda PDGF-B’nın PTE için tanısal bir test olarak kullanılabileceği; yaş, cinsiyet ve kronik hastalıklardan etkilenmediği tespit edildi. Fakat olguların mortalite durumlarını belirlemede anlamlı sonuçlar vermemektedir. Bu çalışma bir ön çalışma olup daha ayrıntılı çalışmaların literatüre bu konuda net bilgi sağlayacağını düşünmekteyiz.
Pulmonary embolism is the most common vascular disease after acute myocardial infarction and stroke. Its prevalence is not clearly known, since mortality is seen in patients without diagnosis. Because of this acute pathology, consequences from right heart failure to sudden cardiac arrest may occur, a prompt diagnosis should be made and treatment should be initiated. Although there are laboratory tests such as D-dimer, their sensitivity is low and new biomarkers are needed. In our study, we wanted to investigate the diagnostic value of PDGFB, which is thought to be one of these markers, in PE cases. Our study was conducted prospectively and as a single center in a third-level university emergency department. Our study included 78 people, 44 patients who met the inclusion criteria, and 34 as the control group. In our study, the significance level was accepted as p <0.05. In our study, the mean age of patients with pulmonary embolism was found to be 68.9 ± 13 (40-96) years. In the patient group, 56.8% (n = 25) of the cases were female and 43.2% (n = 19) were male. The mean PDGF-B level was 994.5 ± 541 in the sick patients and 748 ± 411.5 in the control group, and it was found to be statistically significantly higher than the patient group (p <0.05). No statistical relationship was observed between PDGF-B and age, gender, presence of chronic diseases, vital signs, calculated Geneva, Wells and PESI scores, D-dimer levels and laboratory results, mortality status and echocardiography evaluations. In our study, it was found that PDGF-B can be used as a diagnostic test for PTE; It was determined that it was not affected by age, gender and chronic diseases. However, it does not yield meaningful results in determining the mortality status of the cases. This study is a preliminary study and we think that more detailed studies will provide clear information on this subject to the literature.
Pulmonary embolism is the most common vascular disease after acute myocardial infarction and stroke. Its prevalence is not clearly known, since mortality is seen in patients without diagnosis. Because of this acute pathology, consequences from right heart failure to sudden cardiac arrest may occur, a prompt diagnosis should be made and treatment should be initiated. Although there are laboratory tests such as D-dimer, their sensitivity is low and new biomarkers are needed. In our study, we wanted to investigate the diagnostic value of PDGFB, which is thought to be one of these markers, in PE cases. Our study was conducted prospectively and as a single center in a third-level university emergency department. Our study included 78 people, 44 patients who met the inclusion criteria, and 34 as the control group. In our study, the significance level was accepted as p <0.05. In our study, the mean age of patients with pulmonary embolism was found to be 68.9 ± 13 (40-96) years. In the patient group, 56.8% (n = 25) of the cases were female and 43.2% (n = 19) were male. The mean PDGF-B level was 994.5 ± 541 in the sick patients and 748 ± 411.5 in the control group, and it was found to be statistically significantly higher than the patient group (p <0.05). No statistical relationship was observed between PDGF-B and age, gender, presence of chronic diseases, vital signs, calculated Geneva, Wells and PESI scores, D-dimer levels and laboratory results, mortality status and echocardiography evaluations. In our study, it was found that PDGF-B can be used as a diagnostic test for PTE; It was determined that it was not affected by age, gender and chronic diseases. However, it does not yield meaningful results in determining the mortality status of the cases. This study is a preliminary study and we think that more detailed studies will provide clear information on this subject to the literature.
Açıklama
Anahtar Kelimeler
Pulmoner emboli, Tanı, Biyobelirteç, PDGF-B, Pulmonary embolism, Diagnosis, Biomarker
